Trial Profile
Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial, II (SPORT II)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary) ; Tafluprost
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- Acronyms SPORT II
- 03 Mar 2021 Status changed from recruiting to completed.
- 11 May 2016 Dose of the Bimatoprost changed from 0.1% to 0.01%.
- 24 Apr 2015 New trial record